Smith & Nephew confirms interest in Biomet
This article was originally published in Clinica
Executive Summary
Orthopaedic company Smith & Nephew confirmed today that it has had preliminary talks with US counterpart Biomet regarding a strategic acquisition. A brief statement issued by the London, UK-based company said that no agreement had been reached. Speculation on a merger of the two companies, to form a combined unit with hip sales of $703m and knee sales of $997m, has been building since the US firm and its CEO Dane Miller parted company this spring.
You may also be interested in...
Coronavirus Update: Moderna’s Vaccine Shows Signs Of Lasting Protection
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.
Catchup Capsule: Key APAC Insights You Need To Read
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
QUOTED. 4 December. Eric Borin.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: